secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2025-08-27T23:59:59+00:00
Accession:  0001437749-25-027874
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen shareholders approve 2.75M share increase under 2017 equity plan and new compensation policy
--------------------------------------------------------------------------------

- Shareholders approved amendment to 2017 Equity Incentive Plan, authorizing 2,750,000 additional ordinary shares.
- Shareholders approved Amended and Restated Non-Employee Director and Officer Compensation Policy.
- All seven director nominees elected: Arie Belldegrun, Elizabeth Barrett, Cynthia Butitta, Stuart Holden, James Robinson, Leana Wen, Daniel Wildman.
- Advisory vote on executive compensation approved (18.85M for); one-year frequency for future say-on-pay votes selected.
- PricewaterhouseCoopers LLP ratified as independent auditor with 32.9M votes in favor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000143774925027874/0001437749-25-027874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000143774925027874/urgn20250826_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-027874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer